# A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment

> **NCT05255133** · NA · COMPLETED · sponsor: **Universiteit Antwerpen** · enrollment: 22 (actual)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **OTHER:** Liquid biopsies
- **OTHER:** Scans (CT, gallium-68 DOTATE/TOC/NOC PET-CT)

## Key facts

- **NCT ID:** NCT05255133
- **Lead sponsor:** Universiteit Antwerpen
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-09
- **Primary completion:** 2022-06-23
- **Final completion:** 2022-06-23
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-01-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05255133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05255133, "A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05255133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*